CorMedix Inc.

Listed Company

CRMDCIK 0001410098NasdaqNon-AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$311.71M

Net Income

$163.06M

Total Assets

$826.14M

Equity

$405.31M

Shares Out

78.45M

Op. Cash Flow

$175.05M

CRMD$8.41−23.96% · past yearDBEQ Basic

Daily closing prices

Business

CorMedix Inc. is a biopharmaceutical company that develops and commercializes therapeutic products for life-threatening diseases. The company's primary product is DefenCath, an antimicrobial catheter lock solution for reducing catheter-related bloodstream infections in hemodialysis patients, launched in 2024. In August 2025, CorMedix acquired Melinta Therapeutics, which expanded its portfolio to include six marketed infectious disease products (REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA) and one cardiovascular product (TOPROL-XL), sold through hospital and outpatient care settings. The company pursues expanded indications for DefenCath and REZZAYO while pursuing business development opportunities synergistic with its commercial infrastructure.

Summary from 10-K filed 2026-03-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total Revenues	312	43	—	65,408	190,936
Cost of sales (exclusive of amortization of intangibles)	22	3	—	−3,734	−148,938
Amortization of intangibles	14	156,000	—	—	—
Gross profit	276	40	—	61,674	41,998
Research and development	19	4	−13	−11	−13
Selling and marketing	38	29	−18	—	—
General and administrative	68	30	−18	—	—
Total operating expenses	126	63	−49	−31	−29
Income (Loss) From Operations	150	−22	−49	−31	−29
Interest income	4	3	3	—	—
Foreign exchange transaction loss	−52,000	−31,000	−28,994	37,145	−21,287
Unrealized gain on marketable security	5	—	—	—	—
Other income	—	519,000	—	—	—
Change in contingent consideration	−7	—	—	—	—
Interest expense	−3	−36,000	−34,296	—	—
Total other income (expense)	−125,000	3	3	—	—
Net Income (Loss) Before Income Taxes	150	−19	−46	−30	−29
Income Tax (benefit)	−13	−1	—	585,617	1
Net Income (Loss)	163	−18	−46	−30	−28
Unrealized (loss) from investments	−2,000	−5,000	9,683	5,055	—
Foreign currency translation gain (loss)	−86,000	2,000	1,682	—	—
Total other comprehensive (loss)	−88,000	−3,000	−46	−30	−28
Comprehensive Income (Loss)	163	−18	—	—	—
Net Income (Loss) Per Common Share Basic (in Dollars per share)	2.25	−0.3	−0.91	−0.74	−0.75
Net Income (Loss) Per Common Share Diluted (in Dollars per share)	2.04	−0.3	−0.91	−0.74	−0.75
Weighted Average Common Shares Outstanding Basic (in Shares)	72,034	58,872	51	40	38
Weighted Average Common Shares Outstanding Diluted (in Shares)	80,308	58,872	51	40	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	145	41	44	43	53
Short-term investments	4	11	32	16	12
Account receivables, net	171	52	—	—	—
Inventories	30	8	2	—	3,008
Prepaid expenses and other current assets (including restricted cash of $656 and $0 at December 31, 2025, and December 31, 2024)	18	4	882,214	623,672	770,485
Total current assets	367	115	79	60	66
Property and equipment, net	6	2	2	2	1
Other long-term assets (including restricted cash of $332 and $105 at December 31, 2025, and December 31, 2024, net of current)	24	105,000	—	—	—
Goodwill	30	—	—	—	—
Intangible asset, net	379	2	—	—	—
Deferred tax assets	16	—	—	—	—
Operating lease right-of-use assets, net	3	493,000	640,000	775,000	899,505
Finance lease- right-of-use assets, net	946,000	—	—	—	—
TOTAL ASSETS	826	119	82	62	69
Accounts payable	8	2	4	2	2
Accrued expenses	162	32	7	4	3
Contingent Consideration, short-term	3	—	—	—	—
Operating lease liabilities, short-term	853,000	168,000	151,000	135,000	121,368
Financing lease liability, short-term	596,000	—	—	—	—
Total current liabilities	174	34	11	6	5
Convertible senior notes, net of deferred financing costs	145	—	—	—	—
Contingent Consideration, net of current portion	99	—	—	—	—
Operating lease liabilities, net of current	2	349,000	517,000	668,000	802,433
Finance lease liabilities, net of current	586,000	—	—	—	—
TOTAL LIABILITIES	421	34	12	7	6
COMMITMENTS AND CONTINGENCIES (Note 9)	—	—	—	—	—
Preferred stock - $0.001 par value: 2,000,000 shares authorized; 91,623 and 136,623 shares issued and outstanding at December 31, 2025 and 2024, respectively	—	—	182	182	182
Common stock - $0.001 par value: 160,000,000 shares authorized at December 31, 2025 and 2024; 79,260,667 and 64,411,295 shares issued and outstanding at December 31, 2025 and 2024, respectively	79,000	64,000	54,938	42,815	38,086
Accumulated other comprehensive gain	3,000	91,000	94,108	82,743	87,130
Additional paid-in capital	582	424	392	330	308
Accumulated deficit	−177	−340	−322	−275	−246
TOTAL STOCKHOLDERS EQUITY	405	85	70	55	63
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	826	119	82	62	69

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	14	6	5	4	5
Change in right-of-use assets	438,000	148,000	134,807	124,420	115,130
Depreciation	677,000	154,000	70,755	84,618	61,890
Amortization of intangible	14	200,000	—	—	—
Change in contingent consideration	7	—	—	—	—
Change in fair value of equity securities	−5	—	—	—	—
Deferred income taxes	−26	—	—	—	—
Amortization of debt finance costs	398,000	—	—	—	—
Provision for current expected credit losses	252,000	137,000	—	—	—
Gain on liquidation of foreign entity	−86,000	—	—	—	—
Increase in account receivables	−91	−52	—	—	—
Increase in inventory	−3	−5	−2	3,008	145,456
Increase in prepaid expenses and other current assets	−2	−2	−600,983	187,235	666,628
(Decrease) Increase in accounts payable	3	−3	2	−6,566	—
Increase in accrued expenses	101	23	3	961,963	—
Decrease in operating lease liabilities	−308,000	−151,000	−134,801	−121,368	—
Payment of contingent liability	−61,000	—	—	—	—
Net cash provided by (used in) operating activities	175	−51	−38	−24	−21
Acquisitions of businesses, net of cash acquired	−309	—	—	—	—
Investment in equity securities	−5	—	—	—	—
Purchase of short-term investments	−48	−27	−77	—	—
Maturity of short-term investments	55	48	60	28	8
Purchase of equipment	−2	−116,000	−327,300	−219,360	−1
Net cash provided by (used in) investing activities	−308	21	−17	−4	−9
Proceeds from sale of common stock from public offering, net	82	—	43	—	—
Proceeds from senior convertible notes	150	—	—	—	—
Proceeds from sale of common stock from at-the-market program, net	8	19	13	18	41
Payment of employee withholding taxes on vested restricted stock units	−2	−290,000	−198,443	—	—
Proceeds from exercise of pre-funded warrants	—	3,000	—	128,625	164,886
Proceeds from exercise of stock options	6	8	287,738	—	137,035
Payment of debt issuance costs associated with the convertible notes	−6	—	—	—	—
Payment of contingent consideration liabilities	−189,000	—	—	—	—
ROU financing lease fees	−188,000	—	—	—	—
Net cash provided by financing activities	238	26	56	18	42
Foreign exchange effects on cash	—	−2,000	2,808	−8,677	−12,919
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	105	−3	448,447	−10	11
Cash paid for interest	17,000	36,000	34,296	26,516	15,943
Liability related to license agreement	—	2	9,683	5,055	−4,655
Unpaid debt issuance costs associated with the convertible notes	43,000	—	—	—	—
Issuance of common stock for Melinta acquisition	49	—	—	—	—
Fair value of contingent payments	96	—	—	—	—
ROU assets and liabilities for finance lease	203,000	—	—	—	—
Fair value of assets acquired from Melinta	514	—	—	—	—
Liabilities assumed from Melinta	45	—	—	—	—
Goodwill recognized on Melinta	30	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CorMedix Inc.'s CIK number?

CorMedix Inc.'s SEC CIK number is 0001410098 (1410098). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CorMedix Inc.'s SEC filings?

All of CorMedix Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CorMedix Inc. last report earnings?

CorMedix Inc. (CRMD) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001410098-26-000020). This is CorMedix Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is CorMedix Inc.'s most recent earnings 8-K?

CorMedix Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001410098-26-000020. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CorMedix Inc.'s latest earnings 8-K →
Look up any company's CIK number →